| | | Incidence rate ratio on TTI (95% CI) | value |
| | Age (>30 years) | 1.07 (1.00, 1.14) | 0.051 | | Gender (female) | 0.99 (0.94, 1.04) | 0.612 | | Minority race | 1.12 (1.04, 1.19) | 0.002 | | Charlson/Deyo score ≥ 1 | 0.98 (0.92, 1.06) | 0.677 | | Histology | | | | Osteosarcoma | 1.03 (0.97, 1.09) | 0.316 | | Chondrosarcoma | 0.85 (0.79, 0.92) | <0.001 | | Primary tumor site | | | | Upper extremity | 0.92 (0.85, 0.99) | 0.023 | | Lower extremity | 0.91 (0.86, 0.96) | 0.001 | | Pelvis | 1.26 (1.19, 1.35) | <0.001 | | Tumor size | | | | >8.0 cm | 1.00 (0.95, 1.05) | 0.923 | | Grade | | | | Overall grade | 0.99 (0.97, 1.01) | 0.265 | | Grade 2 vs grade 1 | 1.24 (1.12, 1.38) | <0.001 | | Grade 3 or 4 vs grade 1 | 1.13 (1.03, 1.23) | 0.006 | | Clinical staging | | | | Overall stage | 0.98 (0.98, 0.99) | <0.001 | | Stage II or III | 0.91 (0.85, 0.98) | 0.010 | | Facility type | | | | Academic center | 1.14 (1.08, 1.21) | <0.001 | | Academic center vs comprehensive cancer center | 1.20 (1.11, 1.30) | <0.001 | | Insurance | | | | Private insurance | 0.87 (0.83, 0.92) | <0.001 | | Uninsured vs private insurance | 1.36 (1.21, 1.53) | <0.001 | | Medicaid vs private insurance | 1.22 (1.12, 1.33) | <0.001 | | Medicare vs private insurance | 1.08 (1.01, 1.16) | 0.017 | | Distance to facility ≥21 miles | 0.98 (0.93, 1.03) | 0.520 | | Initial treatment modality | | | | Surgery | 0.88 (0.84, 0.94) | <0.001 | | Transition in care | 1.89 (1.80, 1.99) | <0.001 |
|
|
